SMARCB1 and pancreatic neoplasm: In summary, the current analysis suggests that a subgroup of patients with pancreatic cancer and alterations in SWI/SNF complex chromatin remodeling genes, such as ARID1A, ARID1B, PBRM1, SMARCA4, and SMARCB1, can respond to ICI.